ABBRUPT In 'ABBRUPT' ABBRUPTTrial documentationRecruitment and participating centresCo-EnrolmentPrivacyContact us ABBRUPT is an emergency care trial comparing two treatments for patients in ICU with new onset atrial fibrillation (NOAF) The aim of the ABBRUPT Trial is to find out which treatment works better. LATEST NEWS! ABBRUPT is now open to recruitment. Thank you to our collaborators who have worked so hard to open sites. Design ABBRUPT is a randomised controlled trial to investiagte the clinical and cost effectriveness of Amiodarone vs Beta Blockade for treating new onset atrial fibrillation. Aim of the Study The primary aim of the study is to see how well patients are recovering 90 days after being randomised into the trial. Setting Suitable patients will be identified in Intensive Care Units at NHS Trusts across the UK. Target Population Adult patients in ICU who develop new onset atrial fibrillation. Intervention Participants will be randomised to receive eiether amiodarone or beta blockade. Measurement of outcomes The objectives are: Primary objectives To assess 90 day mortality Secondary objectives To assess ICU and hospital mortality To assess rates of cardiovascular events including stroke, myocardial infarction or thromboembolism up to 90 days To assess the rate of established AF by the end of ICU stay/death/day 90 To assess the number of episodes of bradycardia To assess the number of bradycardia and bradycardic arrhythmias with haemodynamic compromise requiring intervention To assess the number of significant hypotension episodes requiring intervention To assess heart block To assess arrhythmia with haemodynamic compromise requiring intervention including DC cardioversion To assess the cost-effectiveness of the interventions To assess the health care resource use including ICU and hospital length of stay